The global at-home testing kits market is projected to register a substantial CAGR of 6.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation
The Global At-Home Testing Kits Market, By Test Type (Pregnancy Test, HIV Test Kit, Diabetes, Infectious Diseases, Glucose Tests, Ovulation Predictor Test Kit, Drug Abuse Test Kit, and Others), Type (Cassette, Strip, Midstream, Test Panel, Dip Card, and Others), Age (Pediatric, Adult, and Geriatric), Sample Type (Urine, Blood, Saliva, and Others), Usage (Disposable and Reusable), Distribution Channels (Retail Pharmacies, Drug Store, Supermarket/Hypermarket, and Online Pharmacies), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Rest of Middle East and Africa (MEA), Brazil, Argentina, Caribbean, Colombia, Peru, Chile, Panama, Venezuela, and Rest of South America) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the global at-home testing kits market are:
- Growing adoption of self-testing kits
- Easy availability of self-testing kits at pharmacies
- Increase in awareness about the importance of health diagnosis
Market Players
Some of the major players operating in the global at-home testing kits market are:
- Abbott, Siemens Healthcare GmbH
- F. Hoffmann-La Roche Ltd
- Dragerwerk AG & Co. KGaA
- Ascensia Diabetes Care Holdings AG
- Nectar Lifesciences Ltd.
- ACON Laboratories
- Quidel Corporation.
- ARKRAY USA
- BTNX INC.
- Atomo Diagnostics
- Eurofins Scientific
- Piramal Enterprises Ltd.
- Bionime Corporation
- Nova Biomedical
- Cardinal Health
- OraSure Technologies
- Everlywell
- SA Scientific Ltd.
- Clearblue
TABLE OF CONTENTS
1 INTRODUCTION 34
- 1.1 OBJECTIVES OF THE STUDY 34
- 1.2 MARKET DEFINITION 34
- 1.3 OVERVIEW OF GLOBAL AT-HOME TESTING KITS MARKET 34
- 1.4 LIMITATIONS 36
- 1.5 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
- 2.1 MARKETS COVERED 39
- 2.2 GEOGRAPHICAL SCOPE 40
- 2.3 YEARS CONSIDERED FOR THE STUDY 41
- 2.4 CURRENCY AND PRICING 41
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 42
- 2.6 MULTIVARIATE MODELLING 45
- 2.7 GLOBAL AT-HOME TESTING KITS MARKET, BY TEST TYPE 45
- 2.8 MARKET POSITION COVERAGE GRID 46
- 2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
- 2.10 DBMR MARKET POSITION GRID 48
- 2.11 DISTRIBUTOR CHANNEL ANALYSIS 49
- 2.12 SECONDARY SOURCES 50
- 2.13 ASSUMPTIONS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 54
- 4.1 PESTEL ANALYSIS 57
- 4.2 PORTER'S FIVE FORCES 58
5 GLOBAL AT- HOME TESTING KITS MARKET: REGULATIONS 59
- 5.1 REGULATION IN U.S 59
- 5.2 GUIDELINES FOR SELF-TESTING KITS 59
- 5.3 REGULATION IN EUROPE 60
- 5.4 GUIDELINES FOR TESTING KITS 60
- 5.5 REGULATION IN INDONESIA: 60
6 MARKET OVERVIEW 62
- 6.1 DRIVERS 64
- 6.1.1 GROWING ADOPTION OF SELF-TESTING KITS 64
- 6.1.2 EASY AVAILABILITY OF SELF-TESTING KITS AT PHARMACIES 64
- 6.1.3 INCREASE IN AWARENESS ABOUT THE IMPORTANCE OF HIV DIAGNOSIS 64
- 6.1.4 EASE OF USE AND LOW COSTS OF RAPID SELF-TEST KITS 65
- 6.2 RESTRAINTS 65
- 6.2.1 INACCURACY OF RESULTS BY SELF-TESTING KITS 65
- 6.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MANUFACTURING AND DISTRIBUTION OF TESTING KITS 66
- 6.3 OPPORTUNITIES 67
- 6.3.1 ADVENT OF ADVANCED TECHNOLOGIES 67
- 6.3.2 EMERGING NEED FOR RAPID TESTING KITS FOR COVID-19 PANDEMIC 67
- 6.3.3 STRATEGIC INITIATIVES OF KEY PLAYERS 68
- 6.4 CHALLENGES 68
- 6.4.1 HIGH COMPETITION IN THE MEDICAL TECHNOLOGY INDUSTRY 68
- 6.4.2 REDUCTION IN RESEARCH & DEVELOPMENT BUDGETS 69
7 GLOBAL AT-HOME TESTING KITS MARKET, BY TEST TYPE 70
- 7.1 OVERVIEW 71
- 7.2 GLUCOSE TESTS 74
- 7.3 INFECTIOUS DISEASES 74
- 7.4 PREGNANCY TEST 75
- 7.5 DRUG ABUSE TEST KITS 76
- 7.6 HIV TEST KIT 77
- 7.7 OVULATION PREDICTOR TEST KIT 78
- 7.8 OTHERS TEST TYPES 78
8 GLOBAL AT-HOME TESTING KITS MARKET, BY TYPE 80
- 8.1 OVERVIEW 81
- 8.2 CASSETTES 84
- 8.2.1 RETAIL PHARMACIES 85
- 8.2.2 ONLINE PHARMACIES 85
- 8.2.3 DRUG STORE 85
- 8.2.4 SUPERMARKET/HYPERMARKET 85
- 8.3 STRIP 85
- 8.3.1 RETAIL PHARMACIES 86
- 8.3.2 ONLINE PHARMACIES 86
- 8.3.3 DRUG STORE 86
- 8.3.4 SUPERMARKET/HYPERMARKET 86
- 8.4 MIDSTREAM 86
- 8.4.1 RETAIL PHARMACIES 87
- 8.4.2 ONLINE PHARMACIES 87
- 8.4.3 DRUG STORE 87
- 8.4.4 SUPERMARKET/HYPERMARKET 87
- 8.5 DIP CARD 88
- 8.5.1 RETAIL PHARMACIES 88
- 8.5.2 ONLINE PHARMACIES 89
- 8.5.3 DRUG STORE 89
- 8.5.4 SUPERMARKET/HYPERMARKET 89
- 8.6 TEST PANEL 89
- 8.6.1 RETAIL PHARMACIES 90
- 8.6.2 ONLINE PHARMACIES 90
- 8.6.3 DRUG STORE 90
- 8.6.4 SUPERMARKET/HYPERMARKET 90
- 8.7 OTHERS 90
9 GLOBAL AT-HOME TESTING KITS MARKET, BY AGE 92
- 9.1 OVERVIEW 93
- 9.2 ADULT 96
- 9.3 GERIATRIC 96
- 9.4 PEDIATRIC 97
10 GLOBAL AT-HOME TESTING KITS MARKET, BY SAMPLE TYPE 98
- 10.1 OVERVIEW 99
- 10.2 BLOOD 102
- 10.3 URINE 102
- 10.4 SALIVA 103
- 10.5 OTHER SAMPLE TYPES 103
11 GLOBAL AT-HOME TESTING KITS MARKET, BY USAGE 105
- 11.1 OVERVIEW 106
- 11.2 DISPOSABLE 109
- 11.3 REUSABLE 109
12 GLOBAL AT-HOME TESTING KITS MARKET, BY DISTRIBUTION CHANNELS 111
- 12.1 OVERVIEW 112
- 12.2 RETAIL PHARMACIES 115
- 12.3 ONLINE PHARMACIES 115
- 12.4 DRUG STORE 116
- 12.5 SUPERMARKET/HYPERMARKET 116
13 GLOBAL AT-HOME TESTING KITS MARKET, BY REGION 118
- 13.1 OVERVIEW 119
- 13.2 NORTH AMERICA 124
- 13.2.1 U.S. 131
- 13.2.2 CANADA 134
- 13.2.3 MEXICO 137
- 13.3 EUROPE 140
- 13.3.1 GERMANY 147
- 13.3.2 U.K. 150
- 13.3.3 FRANCE 153
- 13.3.4 ITALY 156
- 13.3.5 SPAIN 159
- 13.3.6 NETHERLANDS 162
- 13.3.7 SWITZERLAND 165
- 13.3.8 RUSSIA 168
- 13.3.9 TURKEY 171
- 13.3.10 BELGIUM 174
- 13.3.11 REST OF EUROPE 177
- 13.4 ASIA-PACIFIC 178
- 13.4.1 CHINA 185
- 13.4.2 JAPAN 188
- 13.4.3 INDIA 191
- 13.4.4 SOUTH KOREA 194
- 13.4.5 AUSTRALIA 197
- 13.4.6 SINGAPORE 200
- 13.4.7 INDONESIA 203
- 13.4.8 THAILAND 206
- 13.4.9 MALAYSIA 209
- 13.4.10 PHILIPPINES 212
- 13.4.11 REST OF ASIA-PACIFIC 215
- 13.5 SOUTH AMERICA 216
- 13.5.1 BRAZIL 223
- 13.5.2 ARGENTINA 226
- 13.5.3 REST OF SOUTH AMERICA 229
- 13.6 MIDDLE EAST & AFRICA 230
- 13.6.1 SOUTH AFRICA 238
- 13.6.2 SAUDI ARABIA 241
- 13.6.3 U.A.E 244
- 13.6.4 ISRAEL 247
- 13.6.5 EGYPT 250
- 13.6.6 REST OF MIDDLE EAST & AFRICA 253
14 GLOBAL AT-HOME TESTING KITS MARKET: COMPANY LANDSCAPE 254
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 254
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 255
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 256
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 257
15 SWOT ANALYSIS 258
16 COMPANY PROFILE 259
- 16.1 ABBOTT 259
- 16.1.1 COMPANY SNAPSHOT 259
- 16.1.2 REVENUS ANALYSIS 259
- 16.1.3 COMPANY SHARE ANALYSIS 260
- 16.1.4 PRODUCT PORTFOLIO 260
- 16.1.5 RECENT DEVELOPMENT 260
- 16.2 SIEMENS HEALTHCARE GMBH 261
- 16.2.1 COMPANY SNAPSHOT 261
- 16.2.2 REVENUS ANALYSIS 261
- 16.2.3 PRODUCT PORTFOLIO 262
- 16.2.4 RECENT DEVELOPMENTS 262
- 16.3 F. HOFFMANN- LA ROCHE LTD 263
- 16.3.1 COMPANY SNAPSHOT 263
- 16.3.2 REVENUE ANALYSIS 263
- 16.3.3 COMPANY SHARE ANALYSIS 264
- 16.3.4 PRODUCT PORTFOLIO 264
- 16.3.5 RECENT DEVELOPMENTS 264
- 16.4 BD 265
- 16.4.1 COMPANY SNAPSHOT 265
- 16.4.2 REVENUE ANALYSIS 265
- 16.4.3 PRODUCT PORTFOLIO 266
- 16.4.4 RECENT DEVELOPMENTS 266
- 16.5 DRAGERWERK AG & CO. KGAA 267
- 16.5.1 COMPANY SNAPSHOT 267
- 16.5.2 REVENUE ANALYSIS 267
- 16.5.3 COMPANY SHARE ANALYSIS 268
- 16.5.4 PRODUCT PORTFOLIO 268
- 16.5.5 RECENT DEVELOPMENTS 268
- 16.6 LIFESCAN IP HOLDINGS, LLC 269
- 16.6.1 COMPANY SNAPSHOT 269
- 16.6.2 COMPANY SHARE ANALYSIS 269
- 16.6.3 PRODUCT PORTFOLIO 270
- 16.6.4 RECENT DEVELOPMENTS 270
- 16.7 ASCENSIA DIABETES CARE HOLDINGS AG. 271
- 16.7.1 COMPANY SNAPSHOT 271
- 16.7.2 COMPANY SHARE ANALYSIS 271
- 16.7.3 PRODUCT PORTFOLIO 272
- 16.7.4 RECENT DEVELOPMENTS 272
- 16.8 NECTAR LIFESCIENCES LTD. (RAPIKIT) 273
- 16.8.1 COMPANY SNAPSHOT 273
- 16.8.2 PRODUCT PORTFOLIO 273
- 16.8.3 RECENT DEVELOPMENTS 273
- 16.9 ACON LABORATORIES, INC. 274
- 16.9.1 COMPANY SNAPSHOT 274
- 16.9.2 PRODUCT PORTFOLIO 274
- 16.9.3 RECENT DEVELOPMENTS 274
- 16.10 QUIDEL CORPORATION. 275
- 16.10.1 COMPANY SNAPSHOT 275
- 16.10.2 REVENUE ANALYSIS 275
- 16.10.3 PRODUCT PORTFOLIO 276
- 16.10.4 RECENT DEVELOPMENTS 276
- 16.11 ARKRAY USA, INC. 277
- 16.11.1 COMPANY SNAPSHOT 277
- 16.11.2 PRODUCT PORTFOLIO 277
- 16.11.3 RECENT DEVELOPMENTS 277
- 16.12 BTNX INC. 278
- 16.12.1 COMPANY SNAPSHOT 278
- 16.12.2 PRODUCT PORTFOLIO 278
- 16.12.3 RECENT DEVELOPMENTS 278
- 16.13 ATOMO DIAGNOSTICS 279
- 16.13.1 COMPANY SNAPSHOT 279
- 16.13.2 REVENUE ANALYSIS 279
- 16.13.3 PRODUCT PORTFOLIO 280
- 16.13.4 RECENT DEVELOPMENTS 280
- 16.14 EUROFINS SCIENTIFIC 281
- 16.14.1 COMPANY SNAPSHOT 281
- 16.14.2 REVENUE ANALYSIS 281
- 16.14.3 PRODUCT PORTFOLIO 282
- 16.14.4 RECENT DEVELOPMENTS 282
- 16.15 PIRAMAL ENTERPRISES LTD. 283
- 16.15.1 COMPANY SNAPSHOT 283
- 16.15.2 REVENUE ANALYSIS 283
- 16.15.3 PRODUCT PORTFOLIO 284
- 16.15.4 RECENT DEVELOPMENTS 284
- 16.16 BIONIME CORPORATION 285
- 16.16.1 COMPANY SNAPSHOT 285
- 16.16.2 REVENUE ANALYSIS 285
- 16.16.3 PRODUCT PORTFOLIO 286
- 16.16.4 RECENT DEVELOPMENTS 286
- 16.17 NOVA BIOMEDICAL 287
- 16.17.1 COMPANY SNAPSHOT 287
- 16.17.2 PRODUCT PORTFOLIO 287
- 16.17.3 RECENT DEVELOPMENTS 287
- 16.18 CARDINAL HEALTH. 288
- 16.18.1 COMPANY SNAPSHOT 288
- 16.18.2 REVENUE ANALYSIS 288
- 16.18.3 PRODUCT PORTFOLIO 289
- 16.18.4 RECENT DEVELOPMENTS 289
- 16.19 ORASURE TECHNOLOGIES 290
- 16.19.1 COMPANY SNAPSHOT 290
- 16.19.2 REVENUE ANALYSIS 290
- 16.19.3 PRODUCT PORTFOLIO 291
- 16.19.4 RECENT DEVELOPMENTS 291
- 16.20 BIOLYTICAL LABORATORIES INC. 292
- 16.20.1 COMPANY SNAPSHOT 292
- 16.20.2 PRODUCT PORTFOLIO 292
- 16.20.3 RECENT DEVELOPMENTS 292
- 16.21 EVERLYWELL, INC. 293
- 16.21.1 COMPANY SNAPSHOT 293
- 16.21.2 PRODUCT PORTFOLIO 293
- 16.21.3 RECENT DEVELOPMENTS 293
- 16.22 SA SCIENTIFIC LTD. 294
- 16.22.1 COMPANY SNAPSHOT 294
- 16.22.2 PRODUCT PORTFOLIO 294
- 16.22.3 RECENT DEVELOPMENTS 294
- 16.23 CLEARBLUE (A SUBSIDIARY OF SWISS PRECISION DIAGNOSTICS GMBH) 295
- 16.23.1 COMPANY SNAPSHOT 295
- 16.23.2 PRODUCT PORTFOLIO 295
- 16.23.3 RECENT DEVELOPMENTS 295
- 16.24 BIOSYNEX 296
- 16.24.1 COMPANY SNAPSHOT 296
- 16.24.2 PRODUCT PORTFOLIO 296
- 16.24.3 RECENT DEVELOPMENTS 296
- 16.25 PRIMA LAB SA 297
- 16.25.1 COMPANY SNAPSHOT 297
- 16.25.2 PRODUCT PORTFOLIO 297
- 16.25.3 RECENT DEVELOPMENTS 298
- 16.26 MP BIOMEDICALS. 299
- 16.26.1 COMPANY SNAPSHOT 299
- 16.26.2 PRODUCT PORTFOLIO 299
- 16.26.3 RECENT DEVELOPMENTS 299
- 16.27 STERILAB SERVICES 300
- 16.27.1 COMPANY SNAPSHOT 300
- 16.27.2 PRODUCT PORTFOLIO 300
- 16.27.3 RECENT DEVELOPMENTS 300
- 16.28 CHEMBIO DIAGNOSTICS, INC. 301
- 16.28.1 COMPANY SNAPSHOT 301
- 16.28.2 REVENUE ANALYSIS 301
- 16.28.3 PRODUCT PORTFOLIO 302
- 16.28.4 RECENT DEVELOPMENTS 302
- 16.29 BIOSURE 303
- 16.29.1 COMPANY SNAPSHOT 303
- 16.29.2 PRODUCT PORTFOLIO 303
- 16.29.3 RECENT DEVELOPMENTS 303
- 16.30 SELFDIAGNOSTICS OU 304
- 16.30.1 COMPANY SNAPSHOT 304
- 16.30.2 PRODUCT PORTFOLIO 304
- 16.30.3 RECENT DEVELOPMENTS 304
17 QUESTIONNAIRE 305
18 RELATED REPORTS 308